Original ArticleClinicalCopeptin Plasma Levels are Associated with Decline of Renal Function in Patients with Type 2 Diabetes Mellitus
Section snippets
Study Design and Participants
In a cross-sectional study, patients with T2DM were recruited from the Medical Care Ambulatory Unit/Family Medicine Unit #75 (UMAA/UMF #75) and the Regional General Hospital # 1 (HGR #1), both from the Mexican Social Security Institute (IMSS) in Morelia, Michoacan, Mexico. The study was approved by the Local Research Committee of the HGR #1, IMSS, Morelia, Michoacan, Mexico. All patients signed an informed consent to participate in the study. Inclusion criteria of the patients were: at least
Results
A total of 480 (41% males) patients with T2DM were analyzed. Sixty-seven (14.0%) patients were classified as stage 1 CKD, 142 (29.5%) as stage 2, 97 (20.2%) as stage 3, 31 (6.5%) as stage 4 and 143 (29.8%) as stage 5 CKD, according the K/DOQI Guidelines. The cardiovascular morbidities found were: hypertension in 215 (44.8%) patients, ischemic heart disease in 20 (4.2%), heart failure in 22 (4.6%), peripheral arterial disease in 11 (2.3%), and stroke in 6 (1.3%) patients. Of the studied
Conclusions
In the present study we investigated the effect of renal function and its association with plasma copeptin levels in a sample of Mexican patients with T2DM. We showed that plasma copeptin levels were strongly associated with the eGFR. Plasma copeptin levels progressively increased, while renal function was declined, reaching the highest values in patients with stage 5 CKD. Interestingly, in patients with stage 5 CKD undergoing hemodialysis, there was a trend toward a reduction in plasma
Acknowledgments
M.L.V.T. researched data. A.E.H.M. researched data. A.G.G. reviewed/edited manuscript and researched data. A.R.A.P. researched data. E.G.L. researched data. P.S. contributed to discussion. H.F.G. contributed to discussion. D.R. contributed to discussion. B.L. reviewed/edited manuscript and contributed to discussion. C.A.A. wrote the manuscript.
References (41)
- et al.
Chronic kidney disease a global public health problem: approaches and initiatives – a position statement from kidney disease improving global outcomes
Kidney Int
(2007) - et al.
The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report
Kidney Int
(2011) - et al.
Biomarkers in chronic kidney disease: a review
Kidney Int
(2011) - et al.
Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort
Kidney Int
(2010) - et al.
V1/V2 vasopressin receptor antagonism potentiates renoprotection of ras inhibition in rats with renal mass reduction
Kidney Int
(2009) - et al.
Copeptin: Pathophysiology and potential clinical impact
Adv Med Sci
(2015) Hyponatremia and Hypo-osmolar Disorders
- et al.
Association between Copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register
Diabetes and its complications
(2015) - et al.
Copeptin: role as a novel biomarker in clinical practice
Clin Chim Acta
(2011) - et al.
The effect of renal function and hemodialysis treatment on plasma vasopressin and Copeptin levels
Kidney Int Rep
(2017)
Biomarkers and surrogate endpoint: preferred definitions and conceptual framework
Clin Pharmacol Ther
Serum creatinine as an index of renal function: new insights into old concepts
Clin Chem
Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate
Clin Chem
The urine sediment as a biomarker of kidney damage
Am J Kidney Dis
Albuminuria as a biomarker of renal function
Emerging role of vasopressin
J Assoc Phys India
Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin
Clin hem
Gender and renal function influence plasma levels of copeptin in healthy individuals
Clin Sci (Lond)
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C and creatinine-based methods
Diabetologia
Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients
Transplantation
Cited by (12)
Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy
2020, Archives of Medical ResearchCitation Excerpt :The present study is the only available study reporting the correlation of UACR not only in patients with DM but also with different stages from initiation of diabetes to the onset of its complications (controls, pre diabetes, DM and DM with nephropathy). Although several studies with variable ethnicity and study parameters are available that have reported significant association of copeptin with DM and renal outcomes with few biomarkers of renal function (1,5,27,29–32). According to best of our knowledge this is the first study reporting copeptin levels from healthy controls to pre diabetic stage to the development of DM and then the onset of renal complications.
Long-term health outcomes associated with hydration status
2024, Nature Reviews NephrologyOsteopontin as a Biomarker in Chronic Kidney Disease
2023, BiomedicinesThe role of copeptin in kidney disease
2023, EndocrineVasopressin marker copeptin and the development of renal and metabolic disorders in patients with type 2 diabetes
2022, Ukrainian Journal of Nephrology and DialysisCopeptin as a novel biomarker of cardiometabolic syndrome
2021, Endokrynologia Polska